Amyotrophic lateral sclerosis progression: Iran-ALS clinical registry, a multicentre study

References

• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3:CD001447.
   PubMed Web of Science ®Google Scholar
• Rothstein JD. Therapeutic horizons for amyotrophic lateral sclerosis. Curr Opin Neurobiol. 1996;6:679–87.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–91.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425–31.
   PubMed Web of Science ®Google Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial 'Clinical limits of amyotrophic lateral sclerosis' workshop contributors. J Neurol Sci. 1994;124 (Suppl):96–107.
   PubMed Web of Science ®Google Scholar
• Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998;55:526–8.
   PubMed Web of Science ®Google Scholar
• Compston A. Aids to the investigation of peripheral nerve injuries. Medical Research Council: Nerve Injuries Research Committee. His Majesty's Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the examination of the peripheral nervous system. By Michael O'Brien for the Guarantors of Brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 Figures. Brain. 2010;133:2838–44.
   PubMedGoogle Scholar
• Franchignoni F, Mora G, Giordano A, Volanti P, Chio A. Evidence of multidimensionality in the ALSFRS-R scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry. 2013;84:1340–5.
   PubMed Web of Science ®Google Scholar
• Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neuron disease: the ALSAQ-40. J Neurol. 1999;246 (Suppl 3):16–21.
   PubMed Web of Science ®Google Scholar
• Shamshiri H, Eshraghian MR, Ameli N, Nafissi S. Validation of the Persian version of the 40-item amyotrophic lateral sclerosis assessment questionnaire. Iran J Neurol. 2013;12:102–5.
   PubMedGoogle Scholar
• Crichton N. Information point: Wilks' lambda. J Clin Nurs. 2000;9:381.
   PubMed Web of Science ®Google Scholar
• Sajjadi M, Etemadifar M, Nemati A, Ghazavi H, Basiri K, Khoundabi B, et al. Epidemiology of amyotrophic lateral sclerosis in Isfahan, Iran. Eur J Neurol. 2010;17:984–9.
   PubMed Web of Science ®Google Scholar
• Alavi A, Nafissi S, Rohani M, Zamani B, Sedighi B, Shamshiri H, et al. Genetic analysis and SOD1 mutation screening in Iranian amyotrophic lateral sclerosis patients. Neurobiol Aging. 2013;34:1516.e1–8.
   PubMed Web of Science ®Google Scholar
• Alavi A, Nafissi S, Rohani M, Shahidi G, Zamani B, Shamshiri H, et al. Repeat expansion in C9orf72 is not a major cause of amyotrophic lateral sclerosis among Iranian patients. Neurobiol Aging. 2014;35:267.e1–7.
   PubMed Web of Science ®Google Scholar
• Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotrophic lateral sclerosis: official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. 2009;10:310–23.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Lepore V, et al. ALS multidisciplinary clinic and survival. Results from a population based study in southern Italy. J Neurol. 2007;254:1107–12.
   PubMed Web of Science ®Google Scholar
• Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther. 2011;17:4–31.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007:CD001447.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis: a population based study in Ireland, 1996–2000. J Neurol. 2003;250:473–9.
   PubMed Web of Science ®Google Scholar
• Zoing MC, Burke D, Pamphlett R, Kiernan MC. Riluzole therapy for motor neuron disease: an early Australian experience (1996–2002). J Clin Neurosci. 2006;13:78–83.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V, et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249:609–15.
   PubMed Web of Science ®Google Scholar
• Louwerse ES, Visser CE, Bossuyt PM, Weverling GJ. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium. J Neurol Sci. 1997;152 (Suppl 1):S10–17.
   Google Scholar
• Lee JR, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci. 1995;132:207–15.
   PubMed Web of Science ®Google Scholar
• Tysnes OB, Vollset SE, Aarli JA. Epidemiology of amyotrophic lateral sclerosis in Hordaland county, western Norway. Acta Neurol Scand. 1991;83:280–5.
   PubMed Web of Science ®Google Scholar
• Testa D, Lovati R, Ferrarini M, Salmoiraghi F, Filippini G. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotrophic lateral sclerosis and other motor neuron disorders. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:208–12.
   PubMed Web of Science ®Google Scholar
• del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population based study. Neurology. 2003;60:813–19.
   PubMed Web of Science ®Google Scholar
• Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology. 2002;59:99–103.
   PubMed Web of Science ®Google Scholar
• Marti-Fabregas J, Pradas J, Illa I. Prognostic factors in amyotrophic lateral sclerosis. Neurologia. 1996;11:174–81.
   PubMedGoogle Scholar
• Aksoy D, Cevik B, Solmaz V, Kurt SG. Clinical, demographic and prognostic features of sporadic amyotrophic lateral sclerosis in northern Turkey. Int J Neurosci. 2014;124:68–73.
   PubMed Web of Science ®Google Scholar
• Lopez-Vega JM, Calleja J, Combarros O, Polo JM, Berciano J. Motor neuron disease in Cantabria. Acta Neurol Scand. 1988;77:1–5.
   PubMed Web of Science ®Google Scholar
• Sabatelli M, Madia F, Conte A, Luigetti M, Zollino M, Mancuso I, et al. Natural history of young-adult amyotrophic lateral sclerosis. Neurology. 2008;71:876–81.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al. Predictors of long survival in amyotrophic lateral sclerosis: a population based study. J Neurol Sci. 2008;268:28–32.
   PubMed Web of Science ®Google Scholar
• Chiò A, Calvo A, Mazzini L, Cantello R, Mora G, Moglia C, et al. Extensive genetics of ALS: a population based study in Italy. Neurology. 2012;79:1983–9.
   PubMed Web of Science ®Google Scholar
• Logroscino G1, Traynor BJ, Hardiman O, Chio' A, Couratier P, Mitchell JD, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry. 2008;79:6–11.
   PubMed Web of Science ®Google Scholar